Related-Party Transactions	9 Months Ended
Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	13. Related-Party Transactions In September 2021, the Company entered into a sublease with Sonoma, with whom the Company has common stockholders with board seats. As a part of the sublease, a $4.6 million tenant improvement contribution payment was made by Sonoma, which will be recognized over the term of the sublease. As of September 30, 2021, accrued liabilities and other current liabilities of $0.5 million and other non-current liabilities of $4.1 million were in connection with the sublease with Sonoma. Income of $0.5 million and $1.2 million was recognized in other operating income, net for the three and nine months ended September 30, 2021, respectively. See Note 7, Leases, for more detail on the Sonoma sublease. The Company is party to the GSK Agreement with GSK, who is a holder of more than 10% of the Company’s equity. See Note 3, Collaboration, License and Success Payment Agreements. Deferred revenue of $5.6 million and $6.1 million as of September 30, 2021 and December 31, 2020, respectively, and deferred revenue, net of current portion of $81.9 million and $89.1 million as of September 30, 2021 and December 31, 2020, respectively, were in connection with the GSK Agreement. Revenue recognized in connection with the GSK agreement was $2.6 million and $1.1 million for the three months ended September 30, 2021 and 2020, respectively, and $7.7 million and $5.4 million for the nine months ended September 30, 2021 and 2020, respectively. In March 2020, the Company repurchased 546,806 shares of its Series A convertible preferred stock and 2,032,166 shares of its common stock from a related party. See Note 8, Convertible Preferred Stock and Note 9, Stockholders' Equity.

Related-Party Transactions

9 Months Ended

Sep. 30, 2021

13. Related-Party Transactions

In September 2021, the Company entered into a sublease with Sonoma, with whom the Company has common stockholders with board seats. As a part of the sublease, a $4.6 million tenant improvement contribution payment was made by Sonoma, which will be recognized over the term of the sublease. As of September 30, 2021, accrued liabilities and other current liabilities of $0.5 million and other non-current liabilities of $4.1 million were in connection with the sublease with Sonoma. Income of $0.5 million and $1.2 million was recognized in other operating income, net for the three and nine months ended September 30, 2021, respectively. See Note 7, Leases, for more detail on the Sonoma sublease.

The Company is party to the GSK Agreement with GSK, who is a holder of more than 10% of the Company’s equity. See Note 3, Collaboration, License and Success Payment Agreements. Deferred revenue of $5.6 million and $6.1 million as of September 30, 2021 and December 31, 2020, respectively, and deferred revenue, net of current portion of $81.9 million and $89.1 million as of September 30, 2021 and December 31, 2020, respectively, were in connection with the GSK Agreement. Revenue recognized in connection with the GSK agreement was $2.6 million and $1.1 million for the three months ended September 30, 2021 and 2020, respectively, and $7.7 million and $5.4 million for the nine months ended September 30, 2021 and 2020, respectively.

In March 2020, the Company repurchased 546,806 shares of its Series A convertible preferred stock and 2,032,166 shares of its common stock from a related party. See Note 8, Convertible Preferred Stock and Note 9, Stockholders' Equity.